Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

0.5394
+0.069414.77%
Post-market: 0.5010-0.0384-7.12%19:29 EDT
Volume:302.43K
Turnover:153.26K
Market Cap:18.02M
PE:-0.49
High:0.5394
Open:0.4890
Low:0.4799
Close:0.4700
52wk High:2.06
52wk Low:0.2810
Shares:33.41M
Float Shares:10.20M
Volume Ratio:2.89
T/O Rate:2.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1120
EPS(LYR):-2.9100
ROE:-65.49%
ROA:-36.00%
PB:0.36
PE(LYR):-0.19

Loading ...

Company Profile

Company Name:
Pasithea Therapeutics Corp.
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
5
Office Location:
1111 Lincoln Road,Suite 500,Miami Beach,Florida,United States
Zip Code:
33139
Fax:
- -
Introduction:
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Directors

Name
Position
Lawrence Steinman
Director and Executive Chairman
Tiago Reis Marques
Chief Executive Officer and Director
Alfred Novak
Independent Director
Emer Leahy
Independent Director
Simon Dumesnil
Independent Director

Shareholders

Name
Position
Tiago Reis Marques
Chief Executive Officer and Director
Daniel Schneiderman
Chief Financial Officer
Kartik Krishnan
Chief Medical Officer
Lawrence Steinman
Director and Executive Chairman